Anvisa approves Brazil's first generic semaglutide pen

Brazil's health regulator, Anvisa, said on Tuesday, May 26, that it approved Ozivy, a semaglutide injector pen made by the Brazilian drugmaker EMS ^[1]. It is the first semaglutide-based pen approved in Brazil and uses the same active ingredient as Novo Nordisk's Ozempic, the diabetes and weight-loss drug whose patent expired in Brazil in March ^[1].

The approval is a registration decision, not an immediate arrival in pharmacies. According to Reuters, the drug can only be marketed once Brazil's medicine pricing chamber approves a price cap ^[1]. Separately, for the product to be included in SUS, Brazil's public health system, it must be approved by the country's Health Ministry ^[1]. Neither the price ceiling nor a launch date has been reported.

What EMS says it can make

EMS plans to produce Ozivy at a plant in Sao Paulo state with capacity for up to 40 million pens per year ^[1]. That scale matters because pen-injector manufacturing is the bottleneck that has limited semaglutide supply worldwide; Reuters framed the move as EMS pushing into "a higher-end segment of the global pharmaceutical industry" ^[1]. The chief executive of Grupo NC, which controls EMS, told Reuters in March that the company expected to launch semaglutide pens this year ^[1].

EMS is not alone. Five other synthetic semaglutide applications and one biological version are under review at Anvisa ^[1]. EMS rival Hypera had previously said it also planned to launch its own generic semaglutide this year ^[1]. In other words, Brazil could go from one semaglutide pen supplier to several within months, though the sources do not give a timeline for those pending reviews.

The Reuters report does not say what dose strengths Ozivy will offer, whether it is approved for type 2 diabetes, weight management or both, or how its price will compare with Ozempic in Brazil. Those details are not yet known from the available reporting.

Why it matters for patients

For people in the United States, the direct effect is none: this approval applies only to Brazil, and the patent expiry described in the source is a Brazilian patent ^[1]. Nothing in the reporting changes the availability, price or prescribing of Ozempic, Wegovy or Rybelsus — all semaglutide — in the US.

The indirect significance is about what generic competition looks like once patents lapse in a given country. Brazil is one of the first large markets where the semaglutide patent has expired, so it becomes a test case: how quickly regulators clear copies, how many manufacturers show up, how much production capacity they can build, and how far prices fall once a pricing authority sets a ceiling ^[1]. Brazil's system differs from the US in a key way — a government chamber sets a maximum price before marketing can begin ^[1], a step the US does not have for most drugs.

US readers may also see "generic semaglutide" headlines from overseas and assume the same products are legally available here. They are not covered by this approval, which is specific to Anvisa's registration of EMS's product ^[1]. Whether large-volume manufacturing in Brazil eventually eases global supply or affects supply chains elsewhere is not addressed in the source.

What happens next

• March 2026: Ozempic's patent expired in Brazil ^[1].
• May 26, 2026: Anvisa approved EMS's Ozivy pen ^[1].
• Next: Brazil's medicine pricing chamber must approve a price cap before Ozivy can be sold ^[1]. A separate Health Ministry decision would be needed for coverage through SUS ^[1].
• Also pending: Anvisa is reviewing five more synthetic semaglutide applications and one biological version ^[1], and Hypera has said it intends to launch a generic semaglutide this year ^[1].